Glenmark Pharmaceuticals has informed that a meeting of the Board of Directors of the Company will be held on Thursday, November 5, 2026, to consider and approve the Unaudited Financial Results (both Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2026. Further noted that the notice of the aforesaid meeting is also being made available on the website of the Company in terms of Regulation 46(2) of the SEBI LODR. The Unaudited Financial Results of the Company shall be submitted to the Stock Exchanges after the conclusion of the aforesaid Board Meeting on Thursday, November 5, 2026, and will also be hosted on the website of the Company on the said date and thereafter shall be published in the newspapers, in accordance with the SEBI LODR. Pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015, and Company’s Code of Conduct for Prevention of Insider Trading, the Company has already informed the Stock Exchanges vide its letter dated September 28, 2026 that the window for trading in securities of the Company for the Designated Persons viz, Directors, Key Managerial Personnel, Identified Employees / Persons of the Company including the Immediate Relatives of the Designated Persons and the Connected Persons, etc. would remain closed from October 01, 2026 till the expiry of 48 hours after the declaration of Unaudited Financial results for the quarter and half year ended September 30, 2026 and accordingly, the trading window shall remain closed till Saturday, November 07, 2026 and shall re-open thereafter, i.e. on Sunday, November 08, 2026.
The above information is a part of company’s filings submitted to BSE.
